太景*-KY (4157)

About 太景*-KY

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.

Headquarters: Taipei, TW · Website: https://www.taigenbiotech.com.tw

Frequently asked questions about 太景*-KY (4157)

What is 太景*-KY (4157)?

太景*-KY (4157) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.